<< Effective Colchicine Therapy for Recurrent Pericarditis

AA Batteries: Can they Relieve Pain? >>

Arcalyst for Gout under Review by FDA

November 29, 2011 by Estella .

from Regeneron Pharm
from Regeneron Pharm
Regeneron Pharmaceuticals Inc. announced that FDA will review its drug Arcalyst as a treatment for gout. FDA plans to complete this review by July 30, 2012.

Arcalyst (rilonacept) is currently approved to treat Cryopyrin-Associated Periodic Syndromes (CAPS), a rare genetic anti-inflammatory disease. Regeneron reported $5.5 million in sales of the drug during the third quarter.

Regeneron is a fully integrated biopharmaceutical company markets two main products: Arcalyst (rilonacept) injection for subcutaneous use and Zaltrap (aflibercep) injection. Additional information about Regeneron and recent news releases are available at www.regeneron.com.


Filed under: Gout Treatment and Prevention, Gout Medications.

Tags: arcalyst, rilonacep, fda review, gout treatment, gouty arthritis, new gout drug.


Leave your comment:

Name (required, limit 30 characters):
Email (required, will not be published):
Your Comment:
Veri Code (not case-sensitive):
    
Most Recent Posts
Category
Archives